Novo Nordisk Launches Weight-Loss Drug Wegovy in China Amid Growing Competition
Novo Nordisk has officially introduced its weight-loss drug, Wegovy, to the Chinese market after securing approval from local health authorities in June. The move positions the pharmaceutical giant to compete directly with rival Eli Lilly, whose weight-loss treatment was also approved but has yet to launch in China, the world’s second-largest pharmaceutical market.
With over 180 million people living with obesity in China, the country represents a significant opportunity for pharmaceutical firms. Wegovy, which is administered via injection, is priced at 1,400 yuan (£153; $194) for four doses in China, significantly lower than its cost in the United States.
Chinese patients will need to bear the full cost of the drug, as Wegovy is not included in the national healthcare insurance scheme. Despite the out-of-pocket expense, Novo Nordisk promotes Wegovy as a “safe and effective weight loss option” for overweight and obese individuals in the country, according to a statement on the Chinese social media platform WeChat.
Research indicates that Wegovy can help patients lose over 10% of their body weight, thanks to its active ingredient, semaglutide. This medicine, also found in Novo Nordisk’s type 2 diabetes drug Ozempic, works by controlling blood sugar, reducing appetite, and creating a feeling of fullness.
Since its U.S. launch in 2021, where a month’s supply costs $1,349, Wegovy has become a global sensation. Its popularity has been bolstered by celebrity endorsements, including Elon Musk, and widespread social media attention.
However, concerns persist regarding the drug’s side effects, such as nausea and vomiting, as well as the likelihood of weight regain once patients discontinue treatment. In the UK, health authorities have urged vigilance against misuse of obesity medications, citing instances where non-obese individuals experienced adverse effects from using the drug for weight loss.
The success of Wegovy has propelled Novo Nordisk to the forefront of the pharmaceutical industry, making it Europe’s most valuable company with a market valuation exceeding $440 billion. By entering the Chinese market, Novo Nordisk aims to capitalize on growing demand for weight-management solutions while intensifying competition in a highly lucrative space.



